Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Jones Financial Companies Lllp

Jones Financial Companies Lllp grew its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 113.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,841 shares of the company's stock after buying an additional 7,883 shares during the period. Jones Financial Companies Lllp's holdings in Moderna were worth $617,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MRNA. Janney Montgomery Scott LLC boosted its holdings in shares of Moderna by 6.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 12,767 shares of the company's stock valued at $853,000 after buying an additional 756 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company's stock worth $25,359,000 after purchasing an additional 15,218 shares during the period. SpiderRock Advisors LLC boosted its stake in Moderna by 1,442.5% during the 3rd quarter. SpiderRock Advisors LLC now owns 26,917 shares of the company's stock worth $1,799,000 after purchasing an additional 25,172 shares during the period. Privium Fund Management B.V. boosted its stake in Moderna by 74.0% during the 3rd quarter. Privium Fund Management B.V. now owns 40,482 shares of the company's stock worth $2,705,000 after purchasing an additional 17,221 shares during the period. Finally, Intrinsic Value Partners LLC boosted its stake in Moderna by 91.1% during the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company's stock worth $3,435,000 after purchasing an additional 24,505 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Up 3.8 %

Shares of MRNA opened at $35.61 on Monday. The company has a 50-day simple moving average of $36.60 and a 200-day simple moving average of $48.77. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a market capitalization of $13.74 billion, a PE ratio of -3.84 and a beta of 1.86.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on MRNA shares. Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. HSBC upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target for the company in a research note on Monday, November 18th. UBS Group decreased their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Moderna in a research report on Friday, February 14th. Finally, Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $60.63.

Remove Ads

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.